Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company.
A number of analysts recently weighed in on STVN shares. Citigroup cut their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Morgan Stanley dropped their price objective on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th.
Get Our Latest Stock Analysis on STVN
Institutional Investors Weigh In On Stevanato Group
Stevanato Group Stock Performance
Shares of STVN stock opened at €19.26 ($21.40) on Monday. Stevanato Group has a 52 week low of €16.56 ($18.40) and a 52 week high of €35.56 ($39.51). The firm has a 50 day moving average of €20.34 and a two-hundred day moving average of €22.91. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.74 and a quick ratio of 1.13.
Stevanato Group (NYSE:STVN – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The company had revenue of €259.60 million during the quarter, compared to analysts’ expectations of €254.92 million. During the same quarter last year, the business posted $0.15 earnings per share. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities analysts predict that Stevanato Group will post 0.5 earnings per share for the current fiscal year.
Stevanato Group Company Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Stories
- Five stocks we like better than Stevanato Group
- Investing in the High PE Growth Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Options Trading – Understanding Strike Price
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.